Bioventus reports two million treatments globally with DUROLANE® single-injection hyaluronic acid (HA) product used to treat knee osteoarthritis (OA) pain.
DUROLANE has more clinical studies than any other U.S. single-injection HA, and has shown in studies to provide greater reduction in OA knee pain vs. Sanofi Genzyme’s Synvisc-One®.
DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, DUROLANE SJ, to treat small joints. The NASHA® process yields a high molecular weight stabilized HA, the molecule that provides lubrication and cushioning in a normal joint.
“The U.S. launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer, Bioventus. “In the U.S., more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally. Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”
Bioventus reports two million treatments globally with DUROLANE® single-injection hyaluronic acid (HA) product used to treat knee osteoarthritis (OA) pain.
DUROLANE has more clinical studies than any other U.S. single-injection HA, and has shown in studies to provide greater reduction in OA knee pain vs. Sanofi Genzyme's Synvisc-One®. ...
Bioventus reports two million treatments globally with DUROLANE® single-injection hyaluronic acid (HA) product used to treat knee osteoarthritis (OA) pain.
DUROLANE has more clinical studies than any other U.S. single-injection HA, and has shown in studies to provide greater reduction in OA knee pain vs. Sanofi Genzyme’s Synvisc-One®.
DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, DUROLANE SJ, to treat small joints. The NASHA® process yields a high molecular weight stabilized HA, the molecule that provides lubrication and cushioning in a normal joint.
“The U.S. launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer, Bioventus. “In the U.S., more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally. Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
